SCD and ovarian cancer: That is why our previous study on the inhibition of SCD1/FADS2 could lower the iron-binding capacity and induce the upsurge of the cellular labile iron pool, which in turn, led to deregulated ROS deposit and lipid peroxidation in ovarian cancer cells [53], suggesting novel combination regimens based on FITs would be helpful to improve treatment outcomes.